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Abstract 
Background: Current therapies have changed systemic vasculitis from a disease with a high rate of 
mortality to a chronic curable condition. A limited percentage of patients either remains refractory to 
conventional treatment or experiences dose-limiting side effects. 
Methods: 11 patients (4 affected by idiopathic systemic microscopic polyangiitis, 5 by Wegener’s 
granulomatosis, and 2 by Churg-Strauss syndrome) intolerant or refractory to conventional therapies 
including cyclophosphamide were enrolled. All patients received rituximab as a rescue therapy and were 
followed for 30–54 months. Following rituximab administration, immunosuppressive drugs were rapidly 
tapered and no immunosuppressive maintenance therapy was given. 
Results: Significant decreases in levels of serum creatinine, proteinuria, erythrocyte sedimentation rate, 
Creactive 
protein, and ANCA titers were observed during the follow-up (at least 30 months after rituximab 
administration). Arthralgia and weakness rapidly disappeared in all patients. Out of 7 patients, 5 reported a 
decrease in the degree of paresthesia and in the electrophysiologic parameters. Six months after rituximab 
administration the mean dose of prednisone was 5.5 mg/day. 
Conclusion: In this sample of patients with systemic vasculitis who were refractory or intolerant to more 
conventional treatment, rituximab proved to be safe and effective in a long-term follow-up, and showed 
steroid- and immunosuppressive-sparing effects allowing the persistence of long-lasting remissions without 
maintenance therapy. 
Introduction 
A considerable minority (about 10%) of patients with anti-neutrophil cytoplasmic antibody-associated 
smallvessel vasculitis are refractory to conventional therapy or experience dose-limiting side effects. 
Moreover, despite effective remission of vasculitic disease, a patient’s quality of life often remains 
compromised due to the devastating effects of the current therapies. Novel therapeutic approaches include 
rituximab, a genetically engineered chimeric murine-human monoclonal antibody that binds to CD20, 
which is expressed on human B cells and at a low level on a small subset of T cells [1] . Mechanisms of 
depletion include antibody- and complement-mediated cytotoxicity [2] , the latter being probably involved 
in infusion reactions [3] . Some non-circulating tissue cells seem to bind rituximab but are non-depleted [4] 
. The role of tissue-restricted depletion-refractory B cells and the CD20- expressing T-cell subset in 
conditioning rituximab responsiveness is under investigation. Rituximab has been investigated as an 
optional therapy in small-size-vessel idiopathic systemic angiitis due to the potentially serious toxicities of 
conventional immunosuppressive agents and because of the need of efficacious therapies for cases who 
are refractory or intolerant to standard therapy. Two randomized controlled studies have recently 
supported the efficacy of rituximab in severe cases of ANCA-associated systemic vasculitis [5, 6] . The only 
limit of these important reports was the relative short time of follow-up. The present open study focused 
on a small cohort of difficult patients who could not be recruited in controlled studies and represent about 
5% of the cases of micropolyangiitis with or without granulomatous phenotype censored by the Piedmont 
Registry of Rare Diseases between January 2006 and August 2009 [197 patients including 77 cases of 
systemic microscopic polyangiitis (MPA), 83 Wegener’s granulomatoses (WG) and 37 Churg-Strauss 
syndromes (CS)]. This small percentage came to our tertiarylevel center after previous unsuccessful 
approaches with a conventional treatment. Our interest focused on the long-term effects of rituximab 
given prospectively to this selected cohort of patients, following a 4 + 2 infusion protocol we successfully 
used in other immune-mediated diseases [7–10] . Another novelty of this study was that this intensive 
treatment was associated with long-lasting remissions despite the absence of maintenance 
immunosuppressive therapy and a small maintenance dose of prednisone. 
Methods 
Eleven patients with ANCA-associated vasculitis, 5 women and 6 men, 5 with WG, 4 with MPA, and 2 with 
CS, mean age 57.5 years (range 35–71), mean disease duration 21.8 months (range 6–80), were deemed 
eligible for rituximab therapy. Table 1 summarizes the main clinical features of the patients. 
Seven patients presented with renal involvement: 6 had a biopsy-proven necrotizing extracapillary 
paucimmune glomerulonephritis, while 1 case did not undergo renal biopsy because of concomitant 
anticoagulation 
therapy due to the presence of antiphospholipid antibodies. Sinus involvement (with 
granulomatous lesion in 1 case) and lung nodules were detected in 5 cases, retroorbital granulomata in 2 
patients. Biopsy-proven leukocytoclastic vasculitis and large necrotizing skin ulcers were present in 2 cases. 
Polyneuropathy was observed in 7 patients, while arthralgia and weakness were found in all 9 cases, and 
fever in 6. Six patients (3 WG: patients No. 5, No. 9, No. 11; 2 MPA: No. 3, No. 4, and 1 CS: No. 7) were 
found to be resistant to CYC. One more WG patient (No. 10) was in a relapsing phase albeit an elevated 
cumulative dose of CYC. Another WG patient (No. 6) had a history of severe CYC-induced leukopenia when 
addressed to our center from another hospital because of a life-threatening disease. A MPA patient (No. 2) 
could not be treated with CYC because of a sudden pancytopenia after 1 week of oral treatment at the 
conventional dose (2 mg/kg). One MPA patient (No. 1) and 1 CS CYC-naive patient (No. 8) refused to accept 
the risks of infertility related to CYC treatment. Rituximab was administered intravenously at a dose of 375 
mg/m 2 on days 1, 8, 15 and 22. Two more doses were administered 1 and 2 months after the last 
administration. This scheme was associated with a delayed occurrence of relapses in our own experience in 
other immune-mediated diseases [7–10] . Premedication included oral anti-histamines, acetaminophen 
(500 mg) and deflazacort (60 mg unique administration at the first infusion). Response was evaluated by 
assessing the changes in clinical signs and symptoms and laboratory parameters for at least 12 months. The 
Birmingham Vasculitis Activity Score (BVAS; at study entry and at 12 months) [11] and the Vasculitis 
Damage Index (VDI; at study entry) were also measured [12] . Human anti-chimeric antibodies directed 
against rituximab were quantified using validated antigen-binding tests (RIA), while levels of therapeutic 
antibodies were assessed using validated ELISA, both performed at Sanquin Diagnostic Services 
(Amsterdam, The Netherlands) on a routine base. Serum samples were collected 8 weeks after the last drug 
administration. Due to the low number of patients, mainly descriptive statistical analyses were performed. 
Differences among study groups were analyzed by multifactorial ANOVA. Differences were considered 
statistically significant when two-sided p values were ! 0.05. Statistical analyses were carried out using 
StatView 5.0.1 for Macintosh (SAS Institute Inc., Cary, N.C., USA). 
Results 
Treatment with rituximab resulted in complete depletion of B cells in peripheral blood, as shown by the 
percentage of CD20-positive cells, diminishing from the pretreatment mean value of 16 to 0.05% 7 days 
after the first infusion. Rituximab blood levels, measured 8 weeks after the last administration, were 
undetectable (8 cases) or present in trace amounts (3 patients). Anti-rituximab antibodies were 
undetectable ( ! 12 AU/ml) in every case. Significant decreases in erythrocyte sedimentation rate and 
Creactive 
protein were observed. IgM values also significantly decreased, while IgG declined, after the 6th 
month ( fig. 1 ). Significant declines were also detected for levels of serum creatinine and proteinuria, while 
ANCA titers and visual analogue score already decreased at the first month ( fig. 1 ). Constitutional 
symptoms disappeared or improved, including arthralgia and weakness in all 9 cases and fever in 6 out of 6. 
Paresthesia has been reported to be improved in 5/7 cases 6 months after rituximab infusions. Of note, the 
electrophysiologic parameters, checked at the 6th month in 5 cases, improved considerably in 4 of them. 
Skin ulcers disappeared. Lung nodules improved and completely resolved in 2 cases. Sinus inflammation 
ameliorated in every case, including the patient with granulomatous lesion. Significant improvement was 
observed in the Birmingham Vasculitis Activity Score ( table 2 ). Notably, 6 months after rituximab 
administration the mean dose of prednisone was 5.5 mg/day, and only 1 patient was assuming 
immunosuppressive therapy (No. 2, mycophenolate mofetil 500 mg/day, withdrawn at the 7th month). At 1 
year of follow-up the mean dose of prednisone was 5 mg/day. No relapses were observed in 9 out 11 cases 
during the follow-up ( 1 30 months). Two patients relapsed. Patient No. 6 presented 18 months after 
rituximab with malaise, persistent cough, rhinosinusitis and fever associated with high titer of ANCA. 
Patient No. 8 presented 15 months after rituximab with fever and lung involvement confirmed at CT scan 
associated with increased levels of ESR and CRP. Because of the good previously obtained results, 
retreatment with rituximab (infusion on days 1 and 8, with two more doses administered 1 and 2 months 
after the last administration) was decided in both cases. Both patients showed a complete clinical response 
again. 
Discussion 
General experience and results of quoted randomized controlled trials [13–15] indicate that 10% of 
patients with ANCA-associated vasculitis are cyclophosphamide-resistant. Refractory disease is defined as a 
persistently active illness despite maximally tolerated cyclophosphamide. However, a number of 
confounding factors (e.g. features of permanent damage or associated morbidity) are implicated in this 
definition. Patients undergoing standard immunosuppressive therapy are susceptible to cumulative toxicity 
derived from both iatrogenic effects – especially in the large proportion of the relapsing course of 
ANCAassociated 
vasculitis – and damage related to the disease itself. Moreover, despite effective remission 
induction as measured by validated indices of disease activity, due to the devastating effects of current 
therapies, a patient’s perspective of the impact of the disease on her/his life, as scored by specific 
questionnaire, remains depressed [16] . Infertility and malignancies (especially in the long-term treatment) 
in the young patient, leukopenia and infections in the elderly make standard immunosuppressive treatment 
unappealing and the advent of effective and safer forms of management of ANCA-associated vasculitis 
more than welcome. A major strength of the present study is that it was specifically addressed to the 
rituximab cost-benefit profile with regard to indicators not only of disease activity, but also of extent of 
vasculitis damage, in patients with ANCA-associated vasculitis and frequent renal involvement with poorly 
controlled disease, history of multiple relapses, and treatment with various immunosuppressive agents 
before rituximab therapy. Our study substantially confirms a number of reports which documented clinical 
benefits of rituximab given in addition to oral prednisone [17] , or immunosuppressive drugs including 
cyclophosphamide, methotrexate, azathioprine and mycophenolate mofetil [18–21] . In general, rituximab 
was found to lead to clinical remission by 6 months in over 80% of cases [22] . Non-responders exhibited 
mostly granulomatous, especially retroorbital, manifestations [21] . This was not the case in our patients, 
even though the response appeared to be delayed compared to other involved sites. This favorable profile 
has been recently reported in a retrospective data collection performed from 65 patients receiving 
rituximab for refractory ANCA-associated vasculitis at four centers in the UK. Patients had at least 6 months 
of follow-up. Complete remission occurred in 49 of the 65 patients (75%) while 15 patients experienced 
partial remission. Remission was accompanied by a decrease of prednisone dosage. 38 patients received a 
second course of rituximab. Of these, 84% experienced a second complete remission. No clear relationship 
between B-cell repopulation and relapse could be observed [22] . Based on results of open studies, two 
separated randomized studies were designed to test the efficacy of rituximab as induction therapy 
compared to standard treatment with cyclophosphamide [5, 6] . There were no differences in sustained 
remission or adverse events in a relatively shortterm follow-up. A 4 + 2 protocol of rituximab administration 
was used in the present study. This scheme was associated with a delayed occurrence of relapses in our 
own experience in secondary vasculitis [7–10] where a complete discontinuation of steroids and 
immunosuppressive drugs was often permitted. This explains the substantial steroid- and 
immunosuppressive-sparing effects observed in our patients, who remained in remission for at least 30 
months in 9 of 11 cases, despite the absence of maintenance immunosuppressive therapy. In 2 patients 
(Nos. 6 and 8) a second cycle of infusion of rituximab alone (on days 1 and 8, with two more doses 1 and 2 
months after the last administration) was given because of worsening of clinical settings. Both the patients 
showed a complete clinical response after the second cycle with normalization of the clinical and serologic 
profile. It is still debated if the key mechanism of action of rituximab in vasculitis consists in removing the 
cellular source of the putative pathogenic autoantibodies. This should presuppose that ANCA are produced 
by shortand not long-lived plasma cells [6] . Actually, it seems more likely that rituximab blocks B-
celldependent autoimmune arms unrelated to antibody production such as cytokine production, antigen 
presentation and interactions with T cells and other antigen-presenting cells [23] . Besides, B cells are 
activated in systemic vasculitis and an expansion of the B-cell compartment, which multiplies the number 
of antigen-presenting cells and increases the production of a variety of cytokines, has been observed in 
vasculitis patients [24] . This might explain the longterm effects of rituximab, which often persists beyond 
the B-cell depletion phase. In a long-term observation period (30–54 months), sustained clinical remission 
without immunosuppressive maintenance therapy (and a negligible dose of prednisone since the 6th 
month) was obtained by a 4 + 2 infusion protocol of rituximab in a selected sample of patients with ANCA 
associated vasculitis intolerant or refractory to conventional therapy. 
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Table 1. Demographic and clinical characteristics of patients at baseline 
 
 
Fig. 1. Biochemical profiles of 11 patients with ANCA-associated idiopathic vasculitis with multiorgan 
involvement who had undergone a 4 + 2 infusion protocol of rituximab (375 mg/m 2 ). ESR = Erythrocyte 
sedimentation rate; CRP = C-reactive protein; IgM = immunoglobulin M; IgG = immunoglobulin G; sCr = 
serum creatinine; ANCA = anti-neutrophil cytoplasm antibody; VAS = visual analogue score. *  p<0.05, ** 





Table 2. Clinical characteristics of patients treated with rituximab in follow-up after treatment 
 
 
